HHS Public Access Author manuscript Author Manuscript

J Thorac Oncol. Author manuscript; available in PMC 2017 February 01. Published in final edited form as: J Thorac Oncol. 2016 February ; 11(2): 249–255. doi:10.1016/j.jtho.2015.10.003.

Contemporary analysis of prognostic factors in patients with unresectable malignant pleural mesothelioma (MPM) Andrea Billé, M.D.1,†, Lee M. Krug, M.D.2,‡, Kaitlin M. Woo, M.S.3, Valerie W. Rusch, M.D.1, and Marjorie G. Zauderer, M.D.2 1Thoracic

Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York,

New York

Author Manuscript

2Thoracic

Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York

3Department

of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York

Abstract Introduction—Previous prognostic scoring systems for MPM included patients managed surgically and predated the use of pemetrexed. We analyzed prognostic factors in a contemporary cohort of patients with unresectable MPM who received pemetrexed-based chemotherapy.

Author Manuscript

Methods—This single institution analysis included MPM patients managed non-surgically from 2000–2013. Variables correlated with overall survival (OS) included sex, performance status (PS), asbestos exposure, tumor laterality, histology, clinical stage, initial PET maximum Standardized Uptake Value (SUVmax), hemoglobin, platelet, lymphocyte, white cell (WBC) and neutrophil counts, treatment type, and clinical benefit from treatment. OS was analyzed by Kaplan-Meier method, and significance (p

Contemporary Analysis of Prognostic Factors in Patients with Unresectable Malignant Pleural Mesothelioma.

Previous prognostic scoring systems for malignant pleural mesothelioma (MPM) included patients managed surgically and predated the use of pemetrexed. ...
336KB Sizes 3 Downloads 6 Views